HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis
USA - NASDAQ:HALO - US40637H1095 - Common Stock
70.1 USD
-0.46 (-0.65%)
70.02 USD
-0.08 (-0.11%)
Taking everything into account, HALO scores 7 out of 10 in our fundamental rating. HALO was compared to 533 industry peers in the Biotechnology industry. While HALO has a great profitability rating, there are some minor concerns on its financial health. HALO has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, HALO could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
In the past year HALO was profitable.
In the past year HALO had a positive cash flow from operations.
HALO had positive earnings in each of the past 5 years.
HALO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 26.81%, HALO belongs to the top of the industry, outperforming 97.75% of the companies in the same industry.
The Return On Equity of HALO (118.17%) is better than 99.44% of its industry peers.
Looking at the Return On Invested Capital, with a value of 42.77%, HALO belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HALO is in line with the industry average of 15.88%.
The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
With an excellent Profit Margin value of 47.91%, HALO belongs to the best of the industry, outperforming 98.50% of the companies in the same industry.
In the last couple of years the Profit Margin of HALO has declined.
HALO's Operating Margin of 59.33% is amongst the best of the industry. HALO outperforms 99.81% of its industry peers.
In the last couple of years the Operating Margin of HALO has declined.
Looking at the Gross Margin, with a value of 84.55%, HALO belongs to the top of the industry, outperforming 87.05% of the companies in the same industry.
In the last couple of years the Gross Margin of HALO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, HALO has less shares outstanding
The number of shares outstanding for HALO has been reduced compared to 5 years ago.
HALO has a better debt/assets ratio than last year.
2.2 Solvency
HALO has an Altman-Z score of 5.12. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
HALO has a Altman-Z score of 5.12. This is in the better half of the industry: HALO outperforms 75.23% of its industry peers.
The Debt to FCF ratio of HALO is 2.51, which is a good value as it means it would take HALO, 2.51 years of fcf income to pay off all of its debts.
HALO's Debt to FCF ratio of 2.51 is amongst the best of the industry. HALO outperforms 93.25% of its industry peers.
A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
HALO has a Debt to Equity ratio of 1.59. This is in the lower half of the industry: HALO underperforms 79.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.12 |
ROIC/WACC5.41
WACC7.91%
2.3 Liquidity
HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
HALO has a worse Current ratio (1.59) than 81.43% of its industry peers.
A Quick Ratio of 1.37 indicates that HALO should not have too much problems paying its short term obligations.
The Quick ratio of HALO (1.37) is worse than 82.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.55% over the past year.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
The Revenue has grown by 31.19% in the past year. This is a very strong growth!
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
The Earnings Per Share is expected to grow by 18.25% on average over the next years. This is quite good.
The Revenue is expected to grow by 13.85% on average over the next years. This is quite good.
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 12.45 indicates a correct valuation of HALO.
Based on the Price/Earnings ratio, HALO is valued cheaply inside the industry as 96.62% of the companies are valued more expensively.
HALO is valuated cheaply when we compare the Price/Earnings ratio to 25.51, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 8.62 indicates a reasonable valuation of HALO.
Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 98.12% of the companies are valued more expensively.
HALO is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.45 | ||
| Fwd PE | 8.62 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.25% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 97.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.61 | ||
| EV/EBITDA | 10.72 |
4.3 Compensation for Growth
HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HALO may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 32.65% in the coming years.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y32.65%
5. Dividend
5.1 Amount
HALO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
70.1
-0.46 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.63%
Inst Owner Change15.62%
Ins Owners0.85%
Ins Owner Change-1.06%
Market Cap8.20B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76.25
Price Target77.18 (10.1%)
Short Float %9.78%
Short Ratio5.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)1.4%
PT rev (3m)13.57%
EPS NQ rev (1m)2.21%
EPS NQ rev (3m)3.32%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)11.94%
Revenue NQ rev (1m)0.5%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)5.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.45 | ||
| Fwd PE | 8.62 | ||
| P/S | 6.6 | ||
| P/FCF | 13.61 | ||
| P/OCF | 13.42 | ||
| P/B | 16.27 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.72 |
EPS(TTM)5.63
EY8.03%
EPS(NY)8.14
Fwd EY11.61%
FCF(TTM)5.15
FCFY7.35%
OCF(TTM)5.22
OCFY7.45%
SpS10.63
BVpS4.31
TBVpS-2.24
PEG (NY)0.26
PEG (5Y)N/A
Graham Number23.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.12 |
F-Score8
WACC7.91%
ROIC/WACC5.41
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.62%
EBIT Next 3Y39.07%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.45 and the Price/Book (PB) ratio is 16.27.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.